Nature of Operations and Liquidity - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
	Oct. 30, 2023	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024
Organization And Nature Of Operations [Line Items]
Net Income (Loss)		$ 3,734	$ 9,935
Net cash used in operating activities		129	$ (2,884)
Accumulated deficit		70,755		$ 73,453
Cash and cash equivalents		$ 15,045		$ 11,813
Gyre | Gyre Pharmaceuticals
Organization And Nature Of Operations [Line Items]
Minority interest ownership indirectly holds	65.20%